Market Newsdesk

CHICAGO, Nov. 24, 2020 /PRNewswire/ — McDonald’s is launching a new social challenge that will have everyone feeling the love this holiday season — especially the families who rely on Ronald McDonald House Charities (RMHC^®) when their child becomes critically ill or injured.

For more than four decades, RMHC has supported families with sick and injured children by providing vital resources and helping them stay together during treatment. In an average year, RMHC raises millions thanks to generous donors including McDonald’s customers, employees and franchisees. But 2020 was no average year, and donations to the organization are down due to the pandemic.

To rally much-needed support and awareness for RMHC, now through Dec. 31, McDonald’s will give $100 in your name as part of its $100 million commitment over five years. To participate, just post a photo or video making the RMHC heart symbol (or another supportive message) to Instagram, Twitter, TikTok or Facebook using #HereForRMHC.

Your hands will turn the RMHC mission into a movement, spreading awareness of the critical work this organization does in communities all over the world. To make the RMHC heart symbol:

1. Build the house by forming a diamond with your hands
2. Show us the chimney by pointing your pinky up
3. Put your heart into it by pushing your index fingers down

This year, we’ve all learned the importance of being there for each other, and we’ve learned this lesson the hard way: by not being there. We missed moments of celebration and heartache with our loved ones. And we’ve gotten the smallest taste of what families with sick children experience when they need to seek out faraway care and are forced to stay apart. These families need us now more than ever.

Helping McDonald’s spread the word are Chrissy Teigen and John Legend. “Anyone who knows us, knows that the most important thing to us is family. When you’re able to lean on loved ones, the hard times always get a little easier. We can’t imagine how agonizing it must be when you’re not able to be there with your sick child. We were inspired by McDonald’s longtime commitment to RMHC, and now we want the world to know how we can all take action to support this amazing charity through the #HereForRMHC challenge,” said Teigen and Legend.

The #HereForRMHC challenge begins today and ends on Dec. 31, 2020. To participate, post a photo or video with #HereForRMHC from your public account on Instagram, Twitter, Facebook or TikTok, where McDonald’s is hosting an official challenge starting today.

This is just one way McDonald’s is living its purpose of feeding and fostering communities — a purpose that took on extra resonance in a year when people are leaning on communities more than ever.

“Here at McDonald’s, we believe there’s a difference between being in a community and being part of one. As a company made up of more than 39,000 restaurants around the world, supporting our communities is in our DNA,” said McDonald’s President and CEO Chris Kempczinski. “I’ve been so inspired by the way RMHC is there for families, day and in and day out, during the most difficult times in their lives — that’s what being part of a community is all about. That’s why we’re so proud to support this wonderful organization now and into the future.”

McDonald’s isn’t stopping at the #HereForRMHC challenge — and you don’t have to either! Franchisees around the world are doing wonderful work every day to support RMHC — from McHappy Day^® to Fries for Good to giving customers the opportunity to donate to RMHC all year long via donation boxes, self-ordering kiosks and at the point of sale. Check with participating McDonald’s to see how you can continue to make an impact for RMHC families when you order at McDonald’s restaurants.

For full terms, please visit McD.to/HereForRMHC.

ABOUT McDONALD’S
McDonald’s is the world’s leading global foodservice retailer with over 39,000 locations in over 100 countries. Approximately 93% of McDonald’s restaurants worldwide are owned and operated by independent local business owners.

ABOUT RONALD McDONALD HOUSE CHARITIES
Ronald McDonald House Charities (RMHC), is a non-profit, 501(c)(3) corporation that creates, finds, and supports programs that directly improve the health and well-being of children and their families. Through a global network of over 260 Chapters in 65 countries and regions, RMHC enables, facilitates and supports family-centered care through three core programs: The Ronald McDonald House, the Ronald McDonald Family Room and the Ronald McDonald Care Mobile. RMHC programs help families with ill or injured children stay together and near leading hospitals and health care services worldwide, ensuring they have access to the medical care their child needs while fully supported and actively involved in their child’s care. For more information, visit rmhc.org. Follow RMHC on Twitter, Facebook, Instagram and LinkedIn.

View original content to download multimedia:http://www.prnewswire.com/news-releases/through-hereforrmhc-social-challenge-mcdonalds-will-give-100-in-your-name-to-ronald-mcdonald-house-charities-as-part-of-100-million-commitment-301179556.html

SOURCE McDonald’s Corporation

FRISCO, Texas, Nov. 24, 2020 /PRNewswire/ — Curtis Mathes Corporation (OTC: TLED) subsidiary, Curtis Mathes Therapeutics, Inc. (CMTI) has received 60+ red light therapy (RLT) modules for initial photonics testing and product fabrication.  CMTI’s RLT units will feature a novel spectrum of light that has been shown in the scientific literature to greatly accelerate recovery from various injuries, including burns, lacerations and deep muscle tissue damage. CMTI has already been collecting anecdotal data from numerous study participants using prototype devices to evaluate the efficacy of RLT in the treatment of rheumatoid arthritis, chronic inflammation, and various degenerative neuropathies.  

“While we are in still in the nascent stages with CMTI, the anecdotal evidence that we have collected with our prototype devices has been incredibly encouraging,” said Dr. Zacariah Hildenbrand, Chief Scientific Officer & Board Member, “RLT may not be a panacea; however, it is quite clear that our technologies are able to give those struggling with various inflammation-related conditions, greater mobility and functionality with their extremities even after a short 90-120 second treatment.”

“Our RLT modules were developed on the basis of the best medical research that is currently available in the field of photobiomodulation,” said Eric Hill, Chief Legal Officer & Board Member of Curtis Mathes, “The athletic recovery market aside, CMTI is poised to make a significant impact in the lives of those afflicted by inflammation and degenerative conditions.”

About Curtis Mathes Corporation (TLED): TLED is focused on research, development, manufacturing, and sales of state-of-the-art Solid-State Lighting (SSL) in various frequency-specific lighting technologies industries. www.curtismathes.com  /  www.cmgrowlights.com / YOUTUBE 

Forward Looking Statements:

This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, and could cause actual outcomes and results to differ materially from the current expectations. No forward-looking statement can be guaranteed. Forward-looking statements in the press release should be evaluated together with the many uncertainties that affect TLED’s business and TLED undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

View original content to download multimedia:http://www.prnewswire.com/news-releases/curtis-mathes-to-begin-construction-on-red-light-therapy-devices-301179369.html

SOURCE Curtis Mathes Corporation

PITTSBURGH, Nov. 24, 2020 /PRNewswire/ — DICK’S Sporting Goods, Inc. (NYSE: DKS), the largest U.S.-based, omni-channel sporting goods retailer, today announced that Edward W. Stack, Chairman and Chief Executive Officer, will assume the role of Executive Chairman and continue as Chief Merchant on February 1, 2021.  He also will oversee key strategic growth initiatives for the company.

Mr. Stack has served as Chairman and CEO of DICK’S since he and his siblings bought his father’s two small sporting goods stores in upstate New York in 1984. Under Mr. Stack’s leadership and predominantly through organic growth, DICK’S has become the industry leader, with more than 850 stores and nearly $9 billion in annual revenue. Stack has driven DICK’S omni-channel strategy and investments in logistics and technology, which in 2020 have helped the company’s eCommerce business approach $2 billion in revenue.

The company also announced today that its board of directors unanimously elected Lauren R. Hobart, the current President of DICK’S, as President and CEO, also effective February 1, 2021. Ms. Hobart’s appointment is an important step in the company’s long-term succession plan undertaken by the board and Mr. Stack.

Mr. Stack said, “This is the perfect time for this transition. We have the best management team in the company’s history, and the investments we have made in our people, our stores, and our communities are paying off. I look forward to continuing to lead merchandising, product development and several strategic growth initiatives while supporting Lauren as a trusted advisor. She has proven herself to be a capable, innovative and respected leader who has helped drive our business and our culture.”

“Leading the company that Ed built is truly a privilege and an honor,” Ms. Hobart said. “For nearly 10 years, I have witnessed first-hand his commitment to DICK’S values, to our teammates, customers and the communities we serve. I am fortunate to have Ed as a mentor and look forward to leading the company into this next phase of growth with Ed and our senior management team.”

Ms. Hobart continued, “I also want to thank the board and our 45,000 passionate and dedicated teammates who are so pivotal to our success. I am excited to work closely with them and with other members of the DICK’S family to continue to advance the business and make a meaningful impact on our communities as we look to the future.”

Lawrence Schorr, Lead Independent Director of DICK’S, said, “Ed’s vision, values and leadership have built a company of which we are all proud, and DICK’S is well-positioned for growth. This transition process has been in the works for several years with two primary objectives: Ed’s continued involvement in key areas of the business; and a smooth transition of leadership to a capable and prepared new CEO. Lauren is a valued and forward-thinking leader who has played a vital role in DICK’S success. She embodies all that DICK’S stands for, and the board is confident that Ed and Lauren will continue on this successful journey and drive long-term shareholder value.”

Ms. Hobart brings more than 25 years of finance, consumer and retail experience and spent 14 years at PepsiCo in various leadership roles before she joined DICK’S as Chief Marketing Officer in 2011. She was appointed President in 2017 and joined the board of directors the following year. Since joining DICK’S, Ms. Hobart has revamped the company’s marketing efforts and helped drive its robust eCommerce strategy, among other substantive growth initiatives. She has enhanced the company’s exceptional customer service offering and improved the omni-channel customer experience.

In addition to leading the company through the health and economic crises this year, Mr. Stack and Ms. Hobart have together championed the company’s support of youth sports through its groundbreaking Sports Matter initiative. DICK’S and the DICK’S Sporting Goods Foundation have provided more than $100 million in grants and sponsorships since 2014 to enable more than one million kids the opportunity to play and to raise awareness and address the issue of underfunded youth sports programs nationwide.

DICK’S also reported its third quarter 2020 earnings today. The company looks forward to addressing the leadership transition on its earnings call today at 10 a.m. ET.

About Lauren Hobart

Lauren Hobart currently serves as President of DICK’S Sporting Goods – overseeing the Stores, Marketing, eCommerce, Technology, HR, Legal, and Strategy and Analytics organizations. Additionally, she has served on the DICK’S Board of Directors since January 2018 and is President of the DICK’S Sporting Goods Foundation.

Ms. Hobart joined DICK’S in February 2011 as Senior Vice President and Chief Marketing Officer. In 2015, Ms. Hobart was promoted to Executive Vice President and Chief Marketing Officer and later to Executive Vice President, Chief Customer and Digital Officer. She became President in 2017.

Prior to joining DICK’S, Ms. Hobart had several senior executive roles at PepsiCo, including Chief Marketing Officer of carbonated soft drinks in North America. Prior to PepsiCo, she was at Wells Fargo Bank and at JP Morgan Chase. From 2014 to 2018, Ms. Hobart served as a member of the board of directors of Sonic Corp. She currently serves on the Yum! Brands Board of Directors.

About DICK’S Sporting Goods

Founded in 1948, DICK’S Sporting Goods, Inc. is a leading omni-channel sporting goods retailer offering an extensive assortment of authentic, high-quality sports equipment, apparel, footwear and accessories. As of October 31, 2020, the Company operated 732 DICK’S Sporting Goods locations across the United States, serving and inspiring athletes and outdoor enthusiasts to achieve their personal best through a blend of dedicated teammates, in-store services and unique specialty shop-in-shops dedicated to Team Sports, Athletic Apparel, Golf, Lodge/Outdoor, Fitness and Footwear.

Headquartered in Pittsburgh, DICK’S also owns and operates Golf Galaxy and Field & Stream specialty stores, as well as GameChanger, a youth sports mobile app for scheduling, communications and live scorekeeping. DICK’S offers its products through a dynamic eCommerce platform that is integrated with its store network and provides customers with the convenience and expertise of a 24-hour storefront. For more information, visit the Investor Relations page at dicks.com.

Contact

DICK’S Sporting Goods, 724-273-5552, [email protected]

Forward-Looking Statements Involving Known and Unknown Risks and Uncertainties

This press release includes forward-looking statements concerning the Company’s expectations, anticipations, intentions, beliefs or strategies regarding the future. Investors should not place undue reliance on forward-looking statements as a prediction of actual results or events. These statements can be identified as those that may predict, forecast, indicate or imply future results, performance or advancements and by forward-looking words such as “believe”, “anticipate”, “expect”, “estimate”, “predict”, “intend”, “plan”, “project”, “goal”, “will”, “will be”, “will continue”, “will result”, “could”, “may”, “might” or any variations of such words or other words with similar meanings. Forward-looking statements represent the Company’s current expectations regarding future events and are subject to known and unknown risks and uncertainties, including the risks set forth in the Company’s filings with the Securities and Exchange Commission, that could cause actual events to differ materially from those implied by the forward-looking statements. The Company disclaims and does not undertake any obligation to update or revise any forward-looking statement in this press release, except as required by applicable law or regulation.

Category: Company

View original content to download multimedia:http://www.prnewswire.com/news-releases/dicks-sporting-goods-announces-planned-leadership-succession-301179327.html

SOURCE DICK’S Sporting Goods, Inc.

TSX-V:  GBR   

VANCOUVER, BC, Nov. 24, 2020 /PRNewswire/ – Great Bear Resources Ltd. (the “Company” or “Great Bear”) (TSXV: GBR) (OTCQX: GTBAF) today reported results from its ongoing fully funded $21 million exploration program at its 100% owned flagship Dixie Project, in the Red Lake district of Ontario.

New Drill Result Highlights

Each of the following new drill holes targets 40 – 150 m previously undrilled gaps in the 4,200 metre by 500 metre LP Fault drill grid.  Results are arranged by section, referenced to section 20000. Also see Table 1 for complete results:

• Section 20000: BR-169 assayed 5.56 g/t gold over 38.40 metres, including 11.57 g/t gold over 10.55 metres.

• Section 20075 (75 metres to northwest): BR-159 assayed 5.14 g/t gold over 32.75 metres, including 65.34 g/t gold over 1.65 metres.
• Section 20400 (400 metres to northwest): BR-174 assayed 3.39 g/t gold over 40.10 metres, including 20.63 g/t gold over 5.15 metres.
• Section 20475 (475 metres to the northwest): BR-176 assayed 21.93 g/t gold over 5.50 metres, including 187.00 g/t gold over 0.60 metres.
• Section 20525 (525 metres to the northwest). BR-211 intersected many gold intervals: 6.46 g/t gold over 8.85 metres including 48.10 g/t gold over 1.00 metre; 1.54 g/t gold over 52.00 metres; 1.61 g/t gold over 32.30 metres; and 1.20 g/t gold over 16.25 metres. In aggregate, over 189 metres of >1 g/t gold mineralization were intersected in this drill hole over 358.85 metres of core length starting at bedrock surface.
• Section 20600 (600 metres to northwest): BR-212 assayed 4.69 g/t gold over 101.50 metres, including 41.25 g/t gold over 5.25 metres. The highest-grade central mineralized interval assayed 181.00 g/t gold over 0.50 metres. This is the longest multi-gram gold interval drilled at the project to date and occurs at shallow depths of approximately 80 to 170 vertical metres.

• Section 20975 (975 metres to northwest): BR-194 assayed 5.42 g/t gold over 16.25 metres, including 31.90 g/t gold over 0.50 metres.

Chris Taylor, President and CEO of Great Bear said, “Drill holes reported in this release are from large, 40 – 150 m undrilled gaps and step-outs in the previously completed drill grid. All holes successfully intersected gold mineralization where predicted by our models prior to drilling.  With this release we have now reported results for 198 drill holes at the LP Fault since its discovery just 18 months ago, all of which have intersected gold.  We are preparing to release a preliminary 3D model of the LP Fault and its high-grade gold zones from surface to approximately 400 metres depth along 4.2 kilometres of strike length on November 30, 2020.”

The following summarizes the geological/mineralization model definition drilling process on drill section 20600.  Also refer to the cross section provided inFigure 1, the updated plan map provided in Figure 2, and the updated long section provided in Figure 3:

• As reported above, new drill hole BR-212 on drill section 20600 returned 4.69 g/t gold over 101.50 metres, including 41.25 g/t gold over 5.25 metres.

• This hole was completed as a 43 metre down-dip continuity test of previously reported (October 30, 2019) drill hole BR-037 which had two main mineralized intervals: 1) 5.60 g/t gold over 25.25 metres, including a central high-grade interval which assayed 59.05 g/t gold over 1.05 metres, and 2) 2.01 g/t gold over 66.06 metres, which included a central high-grade interval assaying 35.96 g/t gold over 1.73 metres.
• Similarly, BR-212 is a 73 metre up-dip continuation of the mineralized zone in previously reported drill hole BR-142 (July 6, 2020), which assayed 7.26 g/t gold over 53.5 metres, including 32.39 g/t gold over 4.25 metres.
• Geology, structure and gold mineralization have now been consistently traced between all five drill holes on this section over approximately 400 vertical metres.
• High-grade zones within the larger disseminated gold zone, have been defined and incorporated into the Company’s models as shown on section 20600, defining predictable, structurally controlled, sheet-like geometries of gold mineralization.

• The Company anticipates completing additional drill holes between BR-036 and BR-037, and between BR-142 and BR-067. Average vertical spacing up and down dip from the existing holes will average 50 – 75 metres on this section. Additional drilling will also be undertaken below drill hole BR-067. Mineralization is present from bedrock surface and remains open at depth.

This same model-driven drill process is being repeated on more than 80 individual drill sections across more than 4 kilometres of the central LP Fault zone.  Additional reconnaissance drill sections have also been completed on 400 – 1000 metre spacing along an additional six kilometres of strike length of the LP Fault, for a total of approximately 11 kilometres of drilled strike length.  All holes to date have intersected gold mineralization.   

Table
1
: Current LP Fault drill results. Drill sections are arranged from southeast (top of Table) to northwest (bottom of Table).

A complete assay table for all LP Fault drill holes completed to date is posted to the Company’s web site at www.greatbearresources.ca

Drill collar locations, azimuths and dips for the drill holes included in this release are provided in the table below, and have been posted to the Company’s web site for all LP Fault drill holes.

The Company reminds interested shareholders that a live webinar will take place on Monday, November 30^th at 9:00am PST/12:00pm EST.  Management will be available to answer questions following the presentation.  Online registration and participation details may be found at the following link:

https://us02web.zoom.us/webinar/register/WN_XCKIzugJTFOETejNpYYGyg

Table 2: Coordinates of new drill holes reported in this release (NAD 83).

About the Dixie Project

The Dixie Project is 100% owned, comprised of 9,140 hectares of contiguous claims that extend over 22 kilometres, and is located approximately 25 kilometres southeast of the town of Red Lake, Ontario. The project is accessible year-round via a 15 minute drive on a paved highway which runs the length of the northern claim boundary and a network of well-maintained logging roads.

The Dixie Project hosts two principal styles of gold mineralization:

• High-grade gold in quartz veins and silica-sulphide replacement zones (Dixie Limb, Hinge and Arrow zones). Hosted by mafic volcanic rocks and localized near regional-scale D2 fold axes. These mineralization styles are also typical of the significant mined deposits of the Red Lake district.

• High-grade disseminated gold with broad moderate to lower grade envelopes (LP Fault). The LP Fault is a significant gold-hosting structure which has been seismically imaged to extend to 14 kilometres depth (Zeng and Calvert, 2006), and has been interpreted by Great Bear to have up to 18 kilometres of strike length on the Dixie property. High-grade gold mineralization is controlled by structural and geological contacts, and moderate to lower-grade disseminated gold surrounds and flanks the high-grade intervals. The dominant gold-hosting stratigraphy consists of felsic sediments and volcanic units.

About Great Bear

Great Bear Resources Ltd. is a well-financed gold exploration company managed by a team with a track record of success in mineral exploration.  Great Bear is focused in the prolific Red Lake gold district in northwest Ontario, where the company controls over 330 km² of highly prospective tenure across 5 projects: the flagship Dixie Project  (100% owned), the Pakwash Property (earning a 100% interest), the Dedee Property (earning a 100% interest), the Sobel Property (earning a 100% interest), and the Red Lake North Property (earning a 100% interest) all of which are accessible year-round through existing roads.

QA/QC and Core Sampling Protocols

Drill core is logged and sampled in a secure core storage facility located in Red Lake Ontario.  Core samples from the program are cut in half, using a diamond cutting saw, and are sent to Activation Laboratories in Ontario, an accredited mineral analysis laboratory, for analysis. All samples are analysed for gold using standard Fire Assay-AA techniques. Samples returning over 10.0 g/t gold are analysed utilizing standard Fire Assay-Gravimetric methods.  Pulps from approximately 5% of the gold mineralized samples are submitted for check analysis to a second lab.  Selected samples are also chosen for duplicate assay from the coarse reject of the original sample.  Selected samples with visible gold are also analyzed with a standard 1 kg metallic screen fire assay.  Certified gold reference standards, blanks and field duplicates are routinely inserted into the sample stream, as part of Great Bear’s quality control/quality assurance program (QAQC).  No QAQC issues were noted with the results reported herein. 

Qualified Person and NI 43-101 Disclosure

Mr. R. Bob Singh, P.Geo, Director and VP Exploration, and Ms. Andrea Diakow P.Geo, Exploration Manager for Great Bear are the Qualified Persons as defined by National Instrument 43-101 responsible for the accuracy of technical information contained in this news release.

ON BEHALF OF THE BOARD

“Chris Taylor”                                  

Chris Taylor, President and CEO

Cautionary note regarding forward-looking statements

This release contains certain “forward looking statements” and certain “forward-looking information” as defined under applicable Canadian and U.S. securities laws. Forward-looking statements and information can generally be identified by the use of forward-looking terminology such as “may”, “will”, “should”, “expect”, “intend”, “estimate”, “anticipate”, “believe”, “continue”, “plans” or similar terminology. The forward-looking information contained herein is provided for the purpose of assisting readers in understanding management’s current expectations and plans relating to the future. Readers are cautioned that such information may not be appropriate for other purposes.

Forward-looking information are based on management of the parties’ reasonable assumptions, estimates, expectations, analyses and opinions, which are based on such management’s experience and perception of trends, current conditions and expected developments, and other factors that management believes are relevant and reasonable in the circumstances, but which may prove to be incorrect.

Such factors, among other things, include: impacts arising from the global disruption caused by the Covid-19 coronavirus outbreak, business integration risks; fluctuations in general macroeconomic conditions; fluctuations in securities markets; fluctuations in spot and forward prices of gold or certain other commodities; change in national and local government, legislation, taxation, controls, regulations and political or economic developments; risks and hazards associated with the business of mineral exploration, development and mining (including environmental hazards, industrial accidents, unusual or unexpected formations pressures, cave-ins and flooding); discrepancies between actual and estimated metallurgical recoveries; inability to obtain adequate insurance to cover risks and hazards; the presence of laws and regulations that may impose restrictions on mining; employee relations; relationships with and claims by local communities and indigenous populations; availability of increasing costs associated with mining inputs and labour; the speculative nature of mineral exploration and development (including the risks of obtaining necessary licenses, permits and approvals from government authorities); and title to properties.

Great Bear undertakes no obligation to update forward-looking information except as required by applicable law. Such forward-looking information represents management’s best judgment based on information currently available. No forward-looking statement can be guaranteed and actual future results may vary materially. Accordingly, readers are advised not to place undue reliance on forward-looking statements or information.

View original content to download multimedia:http://www.prnewswire.com/news-releases/great-bear-drills-101-50-m-of-4-69-gt-gold-including-5-25-m-of-41-25-gt-gold-at-lp-fault-provides-update-on-successful-model-test-301179614.html

SOURCE Great Bear Resources Ltd.

DALLAS, Nov. 24, 2020 /PRNewswire/ — Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR^® artificial intelligence (“A.I.”) platform to transform the pace, risk and cost of oncology drug discovery and development, and identify patients who will benefit from its targeted oncology drug candidates, announced that Panna Sharma, CEO and President, will participate in the following investor events in December:

1. Diamond Equity Research Emerging Growth Invitational
   Date/time: December 1, 2020 at 12:20 pm ET
   Zoom Link for Live Event: https://us02web.zoom.us/webinar/register/WN_2S0ftHykTdSY_7HJCjGZAQ

2. hubXchange Virtual US East Coast AI in Drug Discovery Xchange
   Date/time: December 2, 2020 at 12:20 pm ET
   Location: https://www.hub-xchange.com/ai-in-drug-discovery-2020

3. 2020 Benzinga Global Small Cap Conference
   Date/time: December 9, 2020 at 3:30 p.m. ET
   Zoom Link for Live Event: https://us02web.zoom.us/j/89571252065

All meetings and presentations will be held virtually. Investors and media interested in meeting with Panna Sharma should contact Marek Ciszewski, J.D., at: [email protected] or +1.628.777.3167. Registered conference attendees may also request meetings through the respective conference registration system.

About Lantern Pharma
Lantern Pharma (LTRN) is a clinical-stage biopharmaceutical company innovating the repurposing, revitalization and development of precision therapeutics in oncology. We leverage advances in machine learning, genomics, and artificial intelligence by using a proprietary A.I. platform to discover biomarker signatures that help identify patients more likely to respond to our pipeline of cancer therapeutics. Lantern’s focus is to improve the outcome for patients by leveraging our technology to uncover, rescue and develop abandoned or failed drugs. Our current pipeline of three drugs, with two programs in clinical stages and two in preclinical, focuses on cancers that have unique and unmet clinical needs with a clearly defined patient population. We believe that the use of machine learning, genomics and computational methods can help accelerate the revitalization, refocusing and development of small molecule-based therapies. By targeting drugs to patients whose genomic profile identifies them as having the highest probability of benefiting from the drug, this approach represents the potential to deliver best-in-class outcomes. Our team seeks out experienced industry partners, world-class scientific advisors, and innovative clinical-regulatory approaches to assist in delivering cancer therapies to patients as quickly and efficiently as possible. For more information, please visit the company’s website at www.lanternpharma.com or follow the company on Twitter @lanternpharma

Contact:
Marek Ciszewski, JD
Director, Investor Relations
628-777-3167
[email protected]

Forward-looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this press release include, among other things, statements relating to: the potential advantages of our RADR^® platform in identifying drug candidates and patient populations that are likely to respond to a drug candidate; our strategic plans to advance the development of any of our drug candidates; our strategic plans to expand the number of data points that our RADR^® platform can access and analyze; our research and development efforts of our internal drug discovery programs and the utilization of our RADR^® platform to streamline the drug development process; our intention to leverage artificial intelligence, machine learning and genomic data to streamline and transform the pace, risk and cost of oncology drug discovery and development and to identify patient populations that would likely respond to a drug candidate; and our plans to discover and develop drug candidates and to maximize their commercial potential by advancing such drug candidates ourselves or in collaboration with others. Any statements that are not statements of historical fact (including, without limitation, statements to the effect that Lantern Pharma Inc. or our management “believes,” “expects,” “anticipates,” “estimates,” “plans” (and similar expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by the forward-looking statements, such as the impact of the COVID-19 pandemic, the results of our clinical trials, and the impact of competition. Additional factors can be found in the Risk Factors section in our final prospectus, dated June 10, 2020, for our initial public offering, on file with the Securities and Exchange Commission. You may access our June 10, 2020 final prospectus under the investor SEC filings tab of our website at www.lanternpharma.com or on the SEC’s website at www.sec.gov. Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this press release represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/lantern-pharma-announces-upcoming-conference-presentations-301179612.html

SOURCE Lantern Pharma

TORONTO, Nov. 24, 2020 /PRNewswire/ – The Green Organic Dutchman Holdings Ltd. (“TGOD” or the “Company”) (TSX: TGOD) (US: TGODF), a leading producer of premium certified organically grown cannabis, is pleased to announce that it has received an Export Certificate from Health Canada.  This certificate enables TGOD to complete its first shipment of medical cannabis to Germany where it will undergo stability testing, the last step before the Company can commence commercialization in 2021.

“This is an important milestone as we get ready to begin the international shipping of our certified organically grown medical cannabis products.  Germany is the first of several markets that we are planning to supply.  Other countries that we anticipate shipping to in the future are Australia and Mexico,” commented Sean Bovingdon, Interim CEO of TGOD.  “We chose to obtain our EU-GMP certification from Germany because of its high standards and its progressive medical cannabis framework,” added Bovingdon.

About The Green Organic Dutchman Holdings Ltd.
The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (US–OTC: TGODF) is a premium certified organically grown cannabis company focused on the health and wellness market.  Its organic cannabis is cultivated in living soil, as nature intended.  The Company is committed to cultivating a better tomorrow by producing its products responsibly, with less waste and impact on the environment. Its two Canadian facilities have been built to LEED certification standards and its products are sold in recyclable packaging.  In Canada, TGOD sells dried flower and oil, and recently launched a series of next–generation cannabis products such as hash, vapes, organic teas and dissolvable powders.  Through its European subsidiary, HemPoland, the Company also distributes premium hemp CBD oil and CBD-infused topicals in Europe. By leveraging science and technology, TGOD harnesses the power of nature from seed to sale.

TGOD’s Common Shares and warrants issued under the indentures dated November 1, 2017, December 19, 2019, June 12, 2020 and October 23, 2020 trade on the TSX under the symbol “TGOD”, “TGOD.WT”, “TGOD.WS”, “TGOD.WR” and “TGOD.WA”, respectively, and TGODF trades in the US on the OTCQX. For more information on The Green Organic Dutchman Holdings Ltd., please visit www.tgod.ca.

Cautionary Statements

This news release includes statements containing certain “forward–looking information” within the meaning of applicable securities law (“forward–looking statements”). Forward looking statements in this release include, but are not limited to, statements about the completion of validation of the Company’s products for international export, statements about the export of the Company’s medical products for commercial purposes to Germany and other jurisdictions, statements about the timing of international sales of the Company’s products and statements about the Company’s ability to offer certain products in certain jurisdictions.  Forward–looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “should”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions.  Various assumptions were used in drawing the conclusions or making the projections contained in the forward–looking statements throughout this news release. Forward–looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties (including market conditions) and other factors that could cause actual events or results to differ materially from those projected in the forward–looking statements, including those risk factors described in the Company’s most recently filed Annual Information Form available on SEDAR.  The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward–looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

Neither the TSX nor the TSX’s Regulation Services Provider (as that term is defined in the policies of Toronto Stock Exchange) accept responsibility for the adequacy or accuracy of this release.

View original content to download multimedia:http://www.prnewswire.com/news-releases/the-green-organic-dutchman-receives-health-canada-approval-to-export-medical-cannabis-to-europe-301179410.html

SOURCE The Green Organic Dutchman Holdings Ltd.

SAN FRANCISCO, Nov. 24, 2020 /PRNewswire/ — Salesforce (NYSE: CRM), the global leader in CRM, today announced that it will hold its annual Investor Day on Tuesday, Dec. 8 beginning at 10:30 a.m. (PT) / 1:30 p.m. (ET).

The live broadcast and on-demand replay will be available at www.salesforce.com/investorday2020 and at www.salesforce.com/investor. An investor presentation accompanying the program will also be made available at www.salesforce.com/investor at approximately 12:00 p.m. PT on Dec. 8, 2020.

About Salesforce
Salesforce is the global leader in Customer Relationship Management (CRM), bringing companies closer to their customers in the digital age. Founded in 1999, Salesforce enables companies of every size and industry to take advantage of powerful technologies—cloud, mobile, social, internet of things, artificial intelligence, voice and blockchain—to create a 360-degree view of their customers. For more information about Salesforce (NYSE: CRM), visit: www.salesforce.com.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/salesforce-to-hold-annual-investor-day-on-december-8-2020-301179494.html

SOURCE Salesforce

NEW YORK, Nov. 24, 2020 /PRNewswire/ — MindMed (NEO: MMED) (OTCQB: MMEDF) (DE: MMQ), a leading psychedelic medicine biotech company, is establishing a digital medicine division known as Albert. Albert is in the process of assembling and recruiting a leading team of technologists, therapists, and clinical drug development experts to help the company research, develop and build an integrated technical platform and comprehensive toolset aimed at delivering psychedelic inspired medicines and experiential therapies combined with digital therapeutics.

Digital therapeutics are defined as evidence-based therapeutic interventions for patients to prevent, manage, or treat a mental disorder or disease. Pairing digital tools, such as wearables and the latest in machine learning, with psychedelic assisted therapies, can give healthcare providers the ability to optimize and better understand the patient journey and therapeutic outcomes from pre-care through to after-care.

MindMed Co-Founder and Co-CEO J.R. Rahn said, “We believe that the next frontier in psychedelic medicine will be to quantify with great precision psychedelic assisted therapy’s impact on patient populations. This new division will not only build apps, technologies and other platforms to help the patient, but hopefully also make the medical community comfortable with this novel treatment paradigm for mental health and addiction by measuring the potential value to their patient populations and ultimate savings to insurers.”

Recent advancements in digital therapeutics have the potential to enable a real time assessment of efficacy in both clinical trials and real-world settings leading to a more robust understanding of the value of a treatment and long-term impact on patient outcomes.

MindMed’s clinical team under the leadership of President and Head of Clinical Dr. Miri Halperin Wernli is designing an experimental clinical trial that pairs non-hallucinogenic psychedelic inspired medicines such as microdoses of LSD with digital therapeutics to track, engage and influence patient behavior. MindMed intends to announce full details of this clinical trial once MindMed and its scientific collaborators finalize the protocol design for submission to relevant health regulators.

Dr. Miri Halperin Wernli said, “This is a perfect moment for digital medicine solutions to come to patients to help support behavioral change, measure and enhance psychiatric care and health outcomes. Our intention is to use digital therapeutics alongside pharmaceutical medicines to maximize one another’s value to the patient and for the healthcare system. The two classes of medicine, along with psychotherapy and various forms of cognitive behavioral therapies, must be regarded as complementary to enhance outcomes, which will create new opportunities to improve quality of care and patient outcomes and drive behavior change at scale.”

About MindMed

MindMed is a psychedelic medicine biotech company that discovers, develops and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT and an Ibogaine derivative, 18-MC. The MindMed executive team brings extensive biopharmaceutical experience to the company’s groundbreaking approach to developing the next-generation of psychedelic inspired medicines and therapies.

MindMed trades on the Canadian exchange NEO under the symbol MMED. MindMed is also traded in the United States under the symbol MMEDF and in Germany under the symbol MMQ. For more information: www.mindmed.co

MindMed Forward-Looking Statements

This press release includes forward-looking statements that involve risks and uncertainties relating to future events and performance of Mind Medicine (MindMed) Inc. (“MindMed”), and actual events or results may differ materially from these forward-looking statements. Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, MindMed’s and its collaborators’ ability to continue to conduct research and clinical programs, MindMed’s ability to manage its supply chain, product sales of products marketed by MindMed and/or its collaborators (collectively, ” Products”), and the global economy; the nature, timing, and possible success and therapeutic applications of Products and Product candidates and research and clinical programs now underway or planned; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Product candidates and new indications for Products; unforeseen safety issues resulting from the administration of Products and Product candidates in patients, including serious complications or side effects in connection with the use of MindMed’s Products and product candidates in clinical trials; determinations by regulatory and administrative governmental authorities which may delay or restrict MindMed’s ability to continue to develop or commercialize Products; ongoing regulatory obligations and oversight impacting Products, research and clinical programs, and business, including those relating to patient privacy; uncertainty of market acceptance and commercial success of Products and Product candidates and the impact of studies on the commercial success of Products and Product candidates; the availability and extent of reimbursement of Products from third-party payers, including private payer healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; competing drugs and product candidates that may be superior to Products and Product candidates; the extent to which the results from the research and development programs conducted by MindMed or its collaborators may be replicated in other studies and lead to therapeutic applications; the ability of MindMed to manufacture and manage supply chains for multiple products and product candidates; the ability of MindMed’s collaborators, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labelling, distribution, and other steps related to MindMed’s Products and product candidates; unanticipated expenses; the costs of developing, producing, and selling products; the ability of MindMed to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license or collaboration agreement to be cancelled or terminated without any further product success; and risks associated with intellectual property of other parties and pending or future litigation relating thereto, other litigation and other proceedings and government investigations relating to MindMed and its operations, the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on MindMed’s business, prospects, operating results, and financial condition. Any forward-looking statements are made based on management’s current beliefs and judgment. MindMed does not undertake any obligation to update publicly any forward-looking statement.

Media Contact:
[email protected]

View original content:http://www.prnewswire.com/news-releases/mindmed-to-launch-albert-a-digital-medicine-division-for-psychedelic-medicines-301179498.html

SOURCE Mind Medicine (MindMed) Inc.